The largest database of trusted experimental protocols

Dialysis

Dialysis is a medical procedure that removes waste, salts, and excess water from the blood when the kidneys are unable to perform this function effectively.
It is a critical treatment for individuals with kidney failure, also known as end-stage renal disease.
Dialysis can be performed using two main methods: hemodialysis, where blood is filtered through a machine, or peritoneal dialysis, where the lining of the abdomen (peritoneum) is used as a filter.
Dialysis helps to maintain the proper balance of electrolytes and fluids in the body, and can improve symptoms and extend the life expectancy of those with kidney failure.
Effective dialysis research is essential to improve patient outcomes and enhance the quality of life for those relying on this life-sustaining treatment.

Most cited protocols related to «Dialysis»

Our consensus process relied on evidence where available and, in the absence of evidence, consensus expert opinion when possible [7 (link)]. This combined approach has previously led to important practice guidelines that were widely adopted into clinical practice [8 (link)]. In contrast, expert opinion alone can ignore important evidence, whereas evidence-based reviews can be conceptually flawed without expert opinion [9 ]. We conducted the consensus process in three stages: preconference, conference and postconference.
Before the conference, we identified six topics relevant to the field of ARF: definition/classification system for ARF; clinical outcome measures for ARF studies; physiological end-points for ARF studies; animal models of ARF; techniques for assessing and achieving fluid balance in ARF; and information technology in acute dialysis. We selected these topics based on the level of possible clinical impact, the level of controversy, known or suspected variation in practice, potential importance for scientific outcome, potential for development of evidence-based medicine recommendations, and availability of evidence. For each topic we outlined a preliminary set of key questions. We then invited an international panel, predominantly from the fields of nephrology and intensive care, based on their expertise in the fields of analysis. Panelists were assigned to three-person workgroups, with each workgroup addressing one key topic. Each workgroup conducted literature searches related to their topic questions via Medline, PubMed, bibliography of review articles and participants' files. Searches were limited to English language articles. However, articles written in other languages were used when identified by workgroup members. During this stage, the scope of the conference was also more clearly defined.
We conducted a 2-day conference in May 2002 in Vicenza, Italy. We developed summary statements through a series of alternating breakout and plenary sessions. In each breakout session, the workgroup refined key questions, identified the supporting evidence, and generated recommendations and/or directions for future research as appropriate. We generated future research questions by identifying deficiencies in the literature and debating whether more evidence was necessary. Where possible, we also considered pertinent study design issues. Workgroup members presented their findings during plenary sessions, rotating responsibility for presenting to ensure full participation. The workgroup then revised their drafts as needed until a final version was agreed upon. When consensus was not achieved on any individual question by the conclusion of the meeting, deliberations continued by correspondence. When voting was required to settle an issue, a two-thirds majority was required to approve a proposal.
A writing committee assembled the individual reports from the workgroups and each report was edited to conform to a uniform style and for length. Finally, each report was submitted for comments to independent international experts. In this report we present a summary of the proceedings.
Publication 2004
Animal Model Conferences Dialysis Fluid Balance Intensive Care physiology
Definitions of study outcomes are outlined in the Supplementary Appendix. A committee whose members were unaware of the study-group assignments adjudicated the clinical outcomes specified in the protocol. The primary hypothesis was that treatment to reach a systolic blood-pressure target of less than 120 mm Hg, as compared with a target of less than 140 mm Hg, would result in a lower rate of the composite outcome of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Secondary outcomes included the individual components of the primary composite outcome, death from any cause, and the composite of the primary outcome or death from any cause.
We also assessed renal outcomes, using a different definition for patients with chronic kidney disease (eGFR <60 ml per minute per 1.73 m2) at baseline and those without it. The renal outcome in participants with chronic kidney disease at baseline was a composite of a decrease in the eGFR of 50% or more (confirmed by a subsequent laboratory test) or the development of ESRD requiring long-term dialysis or kidney transplantation. In participants without chronic kidney disease at baseline, the renal outcome was defined by a decrease in the eGFR of 30% or more to a value of less than 60 ml per minute per 1.73 m2. Incident albuminuria, defined for all study participants by a doubling of the ratio of urinary albumin (in milligrams) to creatinine (in grams) from less than 10 at baseline to greater than 10 during follow-up, was also a prespecified renal outcome.
Prespecified subgroups of interest for all outcomes were defined according to status with respect to cardiovascular disease at baseline (yes vs. no), status with respect to chronic kidney disease at baseline (yes vs. no), sex, race (black vs. non-black), age (<75 vs. ≥75 years), and baseline systolic blood pressure in three levels (≤132 mm Hg, >132 to <145 mm Hg, and ≥145 mm Hg). We also planned a comparison of the effects of systolic blood-pressure targets on incident dementia, changes in cognitive function, and cerebral small-vessel ischemic disease; these results are not presented here.
Publication 2015
Acute Coronary Syndrome Albumins Cardiovascular Diseases Cardiovascular System Cerebral Small Vessel Diseases Cerebrovascular Accident Chronic Kidney Diseases Cognition Congestive Heart Failure Creatinine Dementia Dialysis EGFR protein, human Kidney Kidney Failure, Chronic Kidney Transplantation Myocardial Infarction Patients Systolic Pressure Urine

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Dialysis Gelatins Lysine methacrylic acid Phosphates Pigs Saline Solution Salts Skin Technique, Dilution
Notes:

The procedure for phage propagation is largely specific for each phage and bacterial host. Here we use propagation conditions for T4 phage and Escherichia coli B bacterial host. It is recommended to use appropriated growth and propagation conditions for your choice of phage and host.

Once a sufficiently high titer phage lysate is obtained please proceed to step 3.

It is recommended to only propagate and purify one phage at a time to prevent cross-contamination.

1| Phage plaque assay for determination of titer (Adams, 1959 )
2A| Phage isolation and propagation via plate lysate
2B| Phage propagation via liquid lysate
3| Phage cleanup (0.22 μm filtering and chloroform)
4| Phage concentration and wash via ultrafiltration
5| Endotoxin removal (Morrison & Leive, 1975 (link); Szermer-Olearnik & Boratyński, 2015 (link))
Notes:

This method is adapted from Szermer-Olearnik & Boratyński (2015) (link), which demonstrates the efficient removal of endotoxins from bacteriophage lysates using water immiscible solvents that are subsequently removed via dialysis. For detailed explanation of the methodology please see Morrison & Leive (1975) (link) and Szermer-Olearnik & Boratyński (2015) (link).

Our adapted method uses a speed vacuum to remove residual organic solvent from phage lysates, instead of the lengthy dialysis washes with similar efficiency.

This step is optional. If you do not require removal of bacterial endotoxins from your phage preparations please go to step 7.

6A| Dialysis removal of organic solvent (Szermer-Olearnik & Boratyński, 2015 (link))
Notes:

This method is adapted from Szermer-Olearnik & Boratyński (2015) (link) and describes the removal of residual organic solvents from phage lysates by dialysis.

Residual organic solvents disable downstream Pierce™ LAL Chromogenic Endotoxin Quantitation assays and must be removed in order to accurately quantify endotoxin concentrations.

Due to the ionic concentration of phage SM buffer used you may end up with greater than the starting volume.

6B| Speed vacuum removal of organic solvent
Notes:

This method is a faster alternative to the dialysis method for the removal of residual organic solvents from phage concentrates.

7| Phage bank storage
Publication 2016
azo rubin S Bacteria Bacteriophage Plaque Assay Bacteriophages Bacteriophage T4 Biological Assay Buffers Chloroform Dialysis Endotoxins Escherichia coli Genetic Engineering Ions isolation Solvents Vacuum Vacuum Extraction, Obstetrical
The SNS-3 items were selected to maximize correlation coefficients with the SNS-8 and objective measures of numeracy while preserving content validity of the SNS-8 and demonstrating comparability of the SNS-3’s and SNS-8’s correlation with measures of health literacy. Six independent adult patient samples from a single academic medical center where the SNS-8 was administered were examined:

ED patients (n=208) completed the Wide Range Achievement Test-4 (WRAT-4 (10 )), Rapid Estimate of Adult Literacy in Medicine (REALM (11 (link))), the reading portion of the Shortened Test of Functional Health Literacy in Adults (S-TOFHLA (12 (link))), and the Brief Health Literacy Screen (BHLS (13 (link), 14 (link))), a subjective measure of health literacy. The SNS-3 items were identified using this study sample (15 (link)).

Patients with kidney disease, half of whom were on dialysis (n=75) and the other half with chronic kidney disease not yet requiring dialysis (n=75) completed the Lipkus numeracy assessment (16 (link)), REALM, and BHLS.

Primary care (PC) outpatients (n=205) completed the WRAT-3 and REALM(17 (link)).

Patients at four outpatient hemodialysis units (n=146) completed the WRAT-3, the math and reading portions of the TOFHLA (12 (link), 18 (link)), the REALM, and the BHLS.

Patients with Type 2 diabetes enrolled from 10 State Health Department clinics (n=318) completed the reading portion of the S-TOFHLA and the 5-item version of the Diabetes Numeracy Test (DNT-5 (19 (link))) as part of a baseline battery for the Partnering to Improve Diabetes Education (PRIDE) study(20 (link)).

Patients with hypertension admitted to a university hospital in the Health Literacy Screening (HEALS) study (21 (link)) (n=460) completed the BHLS and the reading portion of the S-TOFHLA at enrollment.

In a seventh study (Vanderbilt Inpatient Cohort Study, VICS (22 (link))), 2,053 subjects hospitalized for acute coronary syndrome and/or heart failure completed the SNS-3, the BHLS, and STOFHLA.
Surveys were administered by research assistants and completed using pencil/pen and paper in the two kidney disease study cohorts and in the PRIDE study; PRIDE subjects with low health literacy were administered surveys orally by research assistants. In the ED, primary care, HEALS, VICS study cohorts research assistants read the surveys to subjects. Convenience sampling was used for all studies. The SNS-8 (range: 8 – 48) was scored by summing the responses to the eight SNS items after reverse-coding item 7 (“weather”). The SNS-3 (range: 3 – 18) was scored by summing items 1, 4, and 8 from the SNS-8. Internal consistency reliability for the SNS-3 and SNS-8 was computed using Cronbach’s alpha. Spearman’s correlation coefficients were used to calculate all associations between the SNS measures and the other variables. In these secondary analyses, only complete surveys were used. All seven studies received institutional review board approvals, and all subjects gave their informed consent to participate.
Publication 2015
Acute Coronary Syndrome Adult Chronic Kidney Diseases Congestive Heart Failure Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Dialysis Ethics Committees, Research Health Literacy Hemodialysis High Blood Pressures Inpatient Kidney Diseases Outpatients Patients Pharmaceutical Preparations Primary Health Care

Most recents protocols related to «Dialysis»

Example 3

Recombinant Protein Purification

FIG. 5 shows the steps of one of the purifications carried out on the chimera. In the case of GRNLY, this process was shown in an earlier paper [Ibáñez, R., University of Zaragoza. 2015]. It can be seen in FIG. 5A that the P. Pastoris supernatant obtained after induction (lane 1) contains rather diluted proteins. After concentrating same with Pellicom, protein bands are not seen in the permeate (lane 3), but proteins that are much more concentrated than in the supernatant are seen in the concentrate (lane 2). After dialysis (lane 4), the band profile remains similar to the concentrate. Furthermore, protein bands are not seen in the buffer in which the dialysis bag (lane 5) was introduced. Upon addition of the nickel resin, the chimera binds to said resin as it has a histidine tag. After adding the resin (lane 6), the intensity of a band corresponding to a protein of about 40 kDa decreases with respect to the concentrate and dialysate. This band may correspond to the chimera. The fact that this band does not altogether disappear may indicate that the nickel resin was saturated. In the washes performed on the resin, particularly in the first wash (lane 7), it can be seen how the residues of other proteins are removed. Finally, after the elution of the nickel column, a major protein with a molecular weight of about 40 kDa corresponding to the molecular weight of the chimera (lane 11) is clearly observed. As shown in FIG. 5B, it was confirmed by means of immunoblot that this band of about 40 kDa corresponds to the chimera (lane 11). It is also confirmed that the resin was saturated because a band appears in the post-resin dialysis phase (lane 6).

FIG. 6 shows different elution fractions and the pooling of all of them with the exception of elution fraction 1. FIG. 6A shows several bands in the different elution fractions and in the total eluate. The band with the highest intensity has a molecular weight corresponding to the chimera. Furthermore, other bands having intermediate molecular weights are observed, which means that the chimera undergoes partial proteolysis. The band with the second highest intensity has a molecular weight of about 10 kDa, which corresponds to 9-kDa GRNLY, as its molecular weight increases since it is bound to a histidine tag. In FIG. 6B, it was confirmed by means of immunoblot that these bands of about 40 and 10 kDa correspond to the chimeric recombinant protein and to recombinant GRNLY, respectively.

Once the chimera is generated, its functionality must be assured, that is, on one hand the scFv still recognizes the CEA antigen, and on the other hand GRNLY is still cytotoxic.

Patent 2024
Antigens Buffers Chimera Chimeric Proteins, Recombinant Dialysis Dialysis Solutions GNLY protein, human Histidine Immunoblotting Nickel One-Step dentin bonding system Proteins Proteolysis Recombinant Proteins Resins, Plant Staphylococcal Protein A Vision
Not available on PMC !

Example 1

The amniotic fluid first undergoes a two-step dialysis process. First, the amniotic fluid is passed through a 3 kiloDalton (kDa) filter to remove low molecular weight urea and uric acid, in addition to reducing the water content. Second, the amniotic fluid is again passed through a 3 kDa membrane in the presence of a dialysate solution (normal saline), to flush the remainder of the urea and uric acid, while maintaining the volume of the fluid. Cryopreservative is added such that the final product contains equal volumes dialyzed fluid and cryopreservative; therefore, the finished product is approximately 1.5 times more concentrated than the starting fluid. The product is then aliquoted into vials (using aseptic technique) and frozen.

It is contemplated that this removal will not have an impact on the components of the AF thought to confer benefit, such as the hyaluronic acid and other proteins in the fluid.

Patent 2024
Amniotic Fluid Asepsis Dialysis Dialysis Solutions Flushing Freezing Hyaluronic acid Normal Saline Proteins Therapeutics Tissue, Membrane Urea Uric Acid

Example 5

To determine the impact of the amino acid variation of romosozumab PARG (SEQ ID NO: 8) variant as compared to the wild type romosozumab on solubility upon subcutaneous (SC) injection, a dialysis solubility assay was performed on both wild type and PARG (SEQ ID NO: 8) C-terminal variant romosozumab in parallel. This screen entails dialyzing a sample of the romosozumab PARG (SEQ ID NO: 8) C-terminal variant and a sample of the wild-type romosozumab into a solution that simulates the pH and ionic strength of the SC space and monitoring the solubility and physical stability of the antibody in these conditions over a short time period. Samples were formulated at ˜63 mg/mL in formulation buffer (pH 5.2). Then each sample was injected into a dialysis cassette and dialyzed into a PBS buffer to mimic the SC space. Visual observations were made 24 hours after initial dialysis. Wild-type romosozumab typically shows precipitation after 24 hours.

The results show that both molecules precipitate in this analysis but the PARG (SEQ ID NO: 8) C-terminal variant precipitates less and at a slower rate. This suggests that the variant is more resistant to precipitation than wild type, although the variant does not abolish precipitation completely.

Patent 2024
Amino Acids Biological Assay Buffers Dialysis Immunoglobulins Menstruation Disturbances Physical Examination romosozumab Simulate composite resin Subcutaneous Injections
Not available on PMC !

Example 3

To produce the modified antibody (vAb), expiCHO cells were transfected with a vector (pc 3.4-vAbL, pc 3.4-vAbH) containing the gene encoding the modified antibody (vAb) protein and cultured, and the modified antibody was purified using affinity chromatography. An XK16 column packed with the affinity resin MabSelect SuRe™ (GE Healthcare) was equilibrated by flushing with buffer A (25 mM Tris, pH 7.0, 25 mM NaCl), and then the culture was flushed and bound to the affinity resin, and the modified antibody (vAb) protein was eluted with buffer B (25 mM citric acid, pH 3.5). After completion of purification, the column was washed with 0.5 M NaOH, and then packed with 20% ethanol and cold-stored. The pH of the eluted sample was adjusted to 6.0 by adding a suitable amount of 1 M Tris (pH 9.0) thereto. The state of the sample was checked through 10% SDS-PAGE. The obtained modified antibody (vAb) protein was subjected to buffer exchange by dialysis against a buffer containing 10 mM sodium succinate and 30 mM sucrose (pH 6.0).

Patent 2024
Buffers Cells Chromatography, Affinity Citric Acid Cloning Vectors Cold Temperature Dialysis Ethanol Genes Immunoglobulins Proteins Resins, Plant SDS-PAGE Sodium Sodium Chloride Succinate Sucrose Tromethamine
Not available on PMC !

Example 8

The free cysteine on hu4D5Fabv8-(V110C) ThioFab was modified by the bis-maleimido reagent BM(PEO)3 (Pierce Chemical), leaving an unreacted maleimido group on the surface of the antibody. This was accomplished by dissolving BM(PEO)4 in a 50% ethanol/water mixture to a concentration of 10 mM and adding a tenfold molar excess of BM(PEO)3 to a solution containing hu4D5Fabv8-(V110C) ThioFab in phosphate buffered saline at a concentration of approximately 1.6 mg/ml (10 micromolar) and allowing it to react for 1 hour. Excess BM(PEO)3 was removed by gel filtration (HiTrap column, Pharmacia) in 30 mM citrate, pH 6 with 150 mM NaCl buffer. An approximate 10 fold molar excess DM1 dissolved in dimethyl acetamide (DMA) was added to the hu4D5Fabv8-(LC V110C) ThioFab-BMPEO intermediate. Dimethylformamide (DMF) may also be employed to dissolve the drug moiety reagent. The reaction mixture was allowed to react overnight before gel filtration or dialysis into PBS to remove unreacted drug. Gel filtration on 5200 columns in PBS was used to remove high molecular weight aggregates and furnish purified hu4D5Fabv8-(LC V110C) ThioFab-BMPEO-DM1.

By the same protocol, hu4D5Fabv8 (HC A121C) ThioFab-BMPEO-DM1 was prepared.

Patent 2024
Buffers Citrates Cysteine Dialysis dimethylacetamide Dimethylformamide Ethanol Gel Chromatography Molar Pharmaceutical Preparations Phosphates Receptors, Antigen, B-Cell Saline Solution Sodium Chloride

Top products related to «Dialysis»

Sourced in United States, United Kingdom
Slide-A-Lyzer dialysis cassettes are a laboratory equipment designed for dialysis, a process used to remove small molecules from a sample. The cassettes provide a contained and controlled environment for this process, allowing for efficient separation and purification of target molecules.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, Germany, United Kingdom
The Slide-A-Lyzer MINI Dialysis Device is a laboratory equipment used for dialysis. It facilitates the removal or exchange of small molecules from a sample through a membrane.
Sourced in United States, Germany, Belgium, Italy, China, Japan, United Kingdom, France
Methacrylic anhydride is a colorless, pungent-smelling liquid used as a chemical intermediate in the production of various compounds. It is a reactive compound that can be used in the synthesis of other chemicals and materials.
Sourced in United States, Germany, Sao Tome and Principe, India, Brazil, Egypt
A dialysis bag is a semi-permeable membrane pouch used in the process of dialysis. It allows for the selective passage of molecules based on their size, allowing smaller molecules to pass through while retaining larger molecules.
Sourced in Germany, United States, India, United Kingdom, Italy, China, Spain, France, Australia, Canada, Poland, Switzerland, Singapore, Belgium, Sao Tome and Principe, Ireland, Sweden, Brazil, Israel, Mexico, Macao, Chile, Japan, Hungary, Malaysia, Denmark, Portugal, Indonesia, Netherlands, Czechia, Finland, Austria, Romania, Pakistan, Cameroon, Egypt, Greece, Bulgaria, Norway, Colombia, New Zealand, Lithuania
Sodium hydroxide is a chemical compound with the formula NaOH. It is a white, odorless, crystalline solid that is highly soluble in water and is a strong base. It is commonly used in various laboratory applications as a reagent.
Sourced in United States, United Kingdom
SnakeSkin dialysis tubing is a semi-permeable membrane used for the separation and purification of molecules based on their size or molecular weight. It allows the passage of small molecules while retaining larger molecules, facilitating the dialysis process. The tubing is made of regenerated cellulose and is available in various sizes to accommodate different experimental requirements.
Sourced in United States
The Slide-A-Lyzer is a dialysis device designed for the purification and buffer exchange of proteins, peptides, and other macromolecules. It facilitates the efficient removal of small molecules, salts, or other contaminants from sample solutions through the process of dialysis.
Sourced in United States, Germany, India, Spain, Italy
A dialysis membrane is a semi-permeable barrier used in dialysis processes to selectively allow the passage of certain molecules while retaining others. It functions by allowing the diffusion of small molecules, such as water, salts, and waste products, across the membrane while preventing the passage of larger molecules, such as proteins and blood cells.

More about "Dialysis"

Dialysis, a critical treatment for individuals with kidney failure, also known as end-stage renal disease (ESRD), is a medical procedure that removes waste, salts, and excess water from the blood when the kidneys are unable to perform this function effectively.
This life-sustaining treatment can be performed through two main methods: hemodialysis, where blood is filtered through a machine, or peritoneal dialysis, where the lining of the abdomen (peritoneum) is used as a filter.
Effective dialysis research is essential to improve patient outcomes and enhance the quality of life for those relying on this treatment.
Researchers can utilize various tools and materials to facilitate their studies, such as Slide-A-Lyzer dialysis cassettes, FBS (fetal bovine serum), DMSO (dimethyl sulfoxide), Slide-A-Lyzer MINI Dialysis Device, Methacrylic anhydride, dialysis bags, sodium hydroxide, and SnakeSkin dialysis tubing.
These materials and devices can be used to conduct experiments, purify proteins, and study the efficiency and performance of different dialysis protocols.
By leveraging AI-powered tools like PubCompare.ai, researchers can enhance their dialysis research by identifying the most accurate and reproducible approaches from the literature, pre-prints, and patents.
Improving dialysis research outcomes is crucial to maintain the proper balance of electrolytes and fluids in the body, and to extend the life expectancy of those with kidney failure.
The continuous advancements in dialysis technology and research are essential for enhancing the quality of life for individuals relying on this life-sustaining treatment.